Health - Google News: Why Regeneron May Not Profit Much From Today's FDA Approval - Forbes

Health - Google News Google News

Why Regeneron May Not Profit Much From Today's FDA Approval - Forbes Aug 3rd 2012, 16:51 Why Regeneron May Not Profit Much From Today's FDA Approval Forbes The Food and Drug Administration just announced that it approved Zaltrap for colorectal cancer, giving Tarrytown, NY-based Regeneron its third approved drug — an impressive achievement for the still unprofitable biotechnology company. Sanofi, Regeneron Win US Approval for Cancer Medicine ZaltrapBusinessweek FDA approves Sanofi/Regeneron colon cancer drugReuters FDA approves Sanofi colon cancer drugChicago Tribune Bloomberg -Fox Business all 14 news articles »

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions

Posted in: